Alphabet’s Isomorphic Labs is preparing to begin human trials of a drug designed using AI, based on protein modelling ...

Google DeepMind's moonshot, Isomorphic Labs, is gearing up to launch its first ever human trial of AI-designed drugs. The ...

Alphabet’s Isomorphic Labs is preparing to launch human trials of AI-designed drugs, its president, Colin Murdoch, told Fortune. Born from DeepMind’s AlphaFold breakthrough, the company is ...

We’re getting very close,” he added. Isomorphic Labs, the company that spun out from DeepMind in 2021, originated from AlphaFold, an AI system known for accurately predicting protein structures.

Isomorphic Labs sets up U.S. presence, with an eye on clinical trials The Alphabet company, spun off from DeepMind, is hiring a new chief medical officer and adding an office in Cambridge ...

Google DeepMind CEO Demis Hassabis has said that AI can have a serious crack at solving all diseases in the coming years. And ...

Isomorphic Labs, together with Google DeepMind, developed and released AlphaFold 3 in May 2024, a revolutionary AI model that can predict the structure and interactions of all of life's molecules ...

What was it like to track the rising danger of this asteroid, and to ultimately determine that it’d miss us? This is the ...

Google parent Alphabet has drawn on its DeepMind artificial intelligence division to form a drug discovery unit that it calls Isomorphic Labs. The UK-registered company will be able to tap into ...

The study will kick off by testing 300,000 samples – 250,000 first and 50,000 second samples - at the Regeneron Genetics Center in the US, with funding for that stage of the project provided by ...